HomeBIIB • NASDAQ
add
Biogen Inc
$144.69
Makalipas ang Oras ng Trabaho:(1.22%)+1.77
$146.46
Sarado: Okt 13, 4:52:57 PM GMT-4 · USD · NASDAQ · Disclaimer
Nakaraang pagsara
$146.57
Sakop ng araw
$144.65 - $147.56
Sakop ng taon
$110.04 - $194.13
Market cap
21.21B USD
Average na Volume
1.80M
P/E ratio
13.84
Dividend yield
-
Primary exchange
NASDAQ
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Hun 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | 2.65B | 7.33% |
Gastos sa pagpapatakbo | 783.70M | 12.02% |
Net na kita | 634.80M | 8.77% |
Net profit margin | 24.00 | 1.35% |
Kita sa bawat share | 5.47 | 3.60% |
EBITDA | 1.11B | 14.61% |
Aktuwal na % ng binabayarang buwis | 14.68% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Hun 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 2.76B | 44.52% |
Kabuuang asset | 28.33B | 5.69% |
Kabuuang sagutin | 10.70B | -2.00% |
Kabuuang equity | 17.63B | — |
Natitirang share | 146.61M | — |
Presyo para makapag-book | 1.22 | — |
Return on assets | 8.12% | — |
Return on capital | 9.57% | — |
Cash Flow
Net change in cash
| (USD) | Hun 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | 634.80M | 8.77% |
Cash mula sa mga operasyon | 160.90M | -74.29% |
Cash mula sa pag-invest | -57.00M | -112.22% |
Cash mula sa financing | -11.70M | 95.23% |
Net change in cash | 160.50M | -80.77% |
Malayang cash flow | 223.68M | -83.73% |
Tungkol
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
Itinatag
1978
Headquarters
Website
Mga Empleyado
7,605
